Panbela Therapeutics Analyst Ratings
Panbela Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 875.61% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 07/24/2023 | 875.61% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy |
| 07/10/2023 | 875.61% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/13/2023 | 875.61% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/02/2023 | 875.61% | HC Wainwright & Co. | $7 → $16 | Reiterates | → Buy |
| 05/05/2023 | 326.83% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/26/2023 | 326.83% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 03/20/2023 | -8.54% | Maxim Group | → $1.5 | Upgrades | Hold → Buy |
| 01/31/2023 | 509.76% | Roth Capital | → $10 | Reinstates | → Buy |
| 10/12/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 06/28/2021 | 509.76% | Roth Capital | → $10 | Initiates Coverage On | → Buy |
| 03/10/2021 | 387.8% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | 875.61% | HC Wainwright & Co. | → 16 美元 | 重申 | 購買 → 購買 |
| 2023 年 7 月 24 日 | 875.61% | HC Wainwright & Co. | 16 美元 → 16 美元 | 重申 | 購買 → 購買 |
| 07/10/2023 | 875.61% | HC Wainwright & Co. | → 16 美元 | 重申 | 購買 → 購買 |
| 06/13/2023 | 875.61% | HC Wainwright & Co. | → 16 美元 | 重申 | 購買 → 購買 |
| 06/02/2023 | 875.61% | HC Wainwright & Co. | 7 美元 → 16 美元 | 重申 | → 購買 |
| 05/05/2023 | 326.83% | HC Wainwright & Co. | → 7 美元 | 重申 | → 購買 |
| 2023 年 4 月 26 日 | 326.83% | HC Wainwright & Co. | → 7 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/20/2023 | -8.54% | Maxim 集團 | → 1.5 美元 | 升級 | 持有 → 買入 |
| 01/31/2023 | 509.76% | 羅斯資本 | → 10 美元 | 恢復 | → 購買 |
| 2022 年 12 月 10 日 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 2021 年 6 月 28 日 | 509.76% | 羅斯資本 | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/10/2021 | 387.8% | Maxim 集團 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Panbela Therapeutics (PBLA)?
Panbela Therapeutics（PBLA）的目標價格是多少？
The latest price target for Panbela Therapeutics (NASDAQ: PBLA) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $16.00 expecting PBLA to rise to within 12 months (a possible 875.61% upside). 10 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月11日公佈了Panbela Therapeutics（納斯達克股票代碼：PBLA）的最新目標股價。該分析公司將目標股價定爲16.00美元，預計PBLA將在12個月內升至12個月內（可能上漲875.61％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Panbela Therapeutics (PBLA)?
Panbela Therapeutics（PBLA）的最新分析師評級是多少？
The latest analyst rating for Panbela Therapeutics (NASDAQ: PBLA) was provided by HC Wainwright & Co., and Panbela Therapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了Panbela Therapeutics（納斯達克股票代碼：PBLA）的最新分析師評級，Panbela Therapeutics重申了買入評級。
When is the next analyst rating going to be posted or updated for Panbela Therapeutics (PBLA)?
Panbela Therapeutics（PBLA）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Panbela Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Panbela Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Panbela Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Panbela Therapeutics的最新評級是在2023年8月11日公佈的，因此您應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Panbela Therapeutics (PBLA) correct?
分析師對Panbela Therapeutics（PBLA）的評級是否正確？
While ratings are subjective and will change, the latest Panbela Therapeutics (PBLA) rating was a reiterated with a price target of $0.00 to $16.00. The current price Panbela Therapeutics (PBLA) is trading at is $1.64, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Panbela Therapeutics（PBLA）評級，目標股價爲0.00美元至16.00美元。Panbela Therapeutics（PBLA）目前的交易價格爲1.64美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。